Critically ill patients and those who have undergone surgery are at a high risk of developing infectious complications due to, among other reasons, a compromised immune status caused by the inflammatory process they experience(Reference Heller, Fischer and Rössel1). Lipids in parenteral nutrition (PN) provide a major source of energy, essential fatty acids and liposoluble vitamins, as well as cell membrane components and eicosanoid and cytokine precursors, and they are attributed pharmacological functions that may intervene in the clinical course of the disease(Reference Tsekos, Reuter and Stehle2).
The first soya oil-based lipid emulsions were associated with an altered response in inflammatory processes, which was suggested to contribute to greater susceptibility to infection and a poorer clinical outcome(Reference Cury-Boaventura, Gorjao and Martins de Lima3). The concern over this potentially harmful consequence has led to the development of alternative lipid emulsions. Olive oil (OO)-based emulsions provide an immunoneutral option(Reference Cury-Boaventura, Gorjao and Martins de Lima3) with clinical advantages(Reference Cury-Boaventura, Gorjao and Martins de Lima3–Reference Puertollano, Puertollano and Álvarez de Cienfuegos5) and proven tolerance and safety(Reference Goulet, Potter and Antébi4). Fish oil (FO) emulsions are considered immunomodulators due to their capacity to modify both the synthesis of bioactive metabolites such as eicosanoids, released with hydrolysis of cell membrane phospholipids, and cytokine production(Reference Tsekos, Reuter and Stehle2).
Despite these theoretical advances, there are few clinical trials examining the definitive impact of administering a single pharmaconutrient on the patients' clinical outcome(Reference Heller, Rössler and Lits6, Reference Heller, Rösel and Gottschlich7), and none of them directly compares OO and FO.
The primary aim of the present study was to assess the relationship between infection and FO-supplemented PN compared to a standard OO emulsion following a high-risk elective major surgery. The secondary aims included assessment of the patients' anti-inflammatory response and evaluation of the safety of, and tolerance to, these emulsions.
Methods
Setting and study design
A prospective, randomised, double-blind study was performed in a 900-bed, third-level teaching hospital in Barcelona (Spain) in patients undergoing elective gastrointestinal tract major surgery. The sample size was calculated according to one hypothesis based on qualitative variables (50 % reduction in the incidence of infections) and another hypothesis based on quantitative variables (25 % difference in C-reactive protein values) by considering an α error of 5 % and statistical power of 80 %. The final population required was therefore proposed to comprise at least twelve patients per group.
Patients were randomly allocated to two groups by consecutively assigning them a number from a randomisation table. Patients who were assigned an even number were placed in the control group, and those who were assigned an odd number were placed in the intervention group.
Patients and inclusion criteria
The study included adult patients who had undergone an elective gastrointestinal major surgery and required at least 5 d of PN. Patients were excluded for metabolic disease, chronic kidney or liver failure, severe haemorrhagic disorder, unstable diabetes, shock, sepsis, congestive heart disease, acute myocardial infarction, stroke, coma of unknown cause, HIV, dyslipoproteinaemia, neutropaenia, contraindications for lipid administration, current immunosuppressive or antineoplastic treatment, obesity or low weight, PN during the 15 d before hospitalisation, surgical intervention within 30 d before hospitalisation and expected fatal outcome.
Study period
From October 2002 to June 2003, twenty-nine patients were randomised. The study began once the patients had undergone surgery and the need for PN had been established. PN was started the day after the surgery. Patients were followed up from the day of the surgery until the day of discharge from the hospital. Seven different teams participated in the surgical interventions. Patients were hospitalised in the postoperative recovery unit, intensive care unit, and/or general surgery and gastrointestinal wards.
Nutritional intervention
PN was administered as ‘all-in-one’ mixtures that were prepared daily in the Pharmacy Service, and was delivered in masked containers. Neither the patient nor the expert assessor knew which lipid emulsion was being used. All PN formulas were administered using an infusion pump over 24 h. Oral or enteral ingestion was not allowed.
Group A (control) received PN with OO lipid emulsion, and group B (intervention) received PN where a part of the OO emulsion had been substituted by FO in a proportion of 16·6 % (w/w), providing the same final amount of lipids.
Both groups received the same supply of nitrogen (0·2–0·3 g/kg per d), energies (83·7–125.5 kJ/kg per d or 20–30 kcal/kg per d) and lipids (0·7–1 g/kg per d). All patients received the same solution of amino acids and glucose (Aminomix®; Fresenius-Kabi, Barcelona, Spain), vitamins (Cernevit®; Baxter, Madrid, Spain) and trace elements (Addamel®; Fresenius-Kabi). Commercial preparations were used for the administration of FO (Omegaven®; Fresenius-AB, Bad Homburg, Germany) and OO (Clinoleic®; Baxter). OO emulsions contain 20 % soya oil. They are rich in long-chain MUFA, mainly n-9, and contain 20 % PUFA with an 8:1 ratio of n-6:n-3. FO-based lipids, rich in n-3 PUFA, present a 1:8 ratio of n-6:n-3, and contain high amounts of n-3 family fatty acids (EPA and DHA) and vitamin E.
Blood extraction
Analytical parameters were determined on the day of the surgery, before starting PN, on day 6 and after 5 d of PN administration. Blood was drawn at approximately 07.00 hours. Determinations were performed at the Clinical Laboratory of our hospital, which has been certified according to the UNE-EN-ISO 15189:2003 standard.
Clinical follow-up
Follow-up included daily monitoring of vital signs, allergic reactions, signs of infection, cardiac alterations, gastrointestinal tract dysfunction, lung processes, renal or hepatic dysfunction, haematological signs and behavioural disorders. Concomitant medication, fluid replacement therapy and blood administration were recorded.
Clinical outcome
The incidence of death, sepsis and non-septic infection was recorded, as well as both the number of hospitalisation days and the days PN treatment was received. Non-septic infection was established by clinical evidence and at least one positive culture from samples of lung (sputum or bronchoalveolar lavage), urine, blood, abdomen (peritoneal fluid or abdominal abscess) or surgical wound. Sepsis was defined on the basis of at least one positive culture plus two or more of the following conditions: leucocytes>12 × 109 cells/l or < 4 × 109 cells/l, body temperature < 35°C or >38°C, heart rate>90/min and PaCO2 < 32 mmHg.
Inflammatory response
The evolution of the inflammatory response was determined by C-reactive protein, prealbumin and leucocyte count after 5 d of PN.
Safety of the infusion
TAG and glucose metabolism, hepatic function (γ-glutamyltransferase, alkaline phosphatase and alanine aminotransferase) and renal function (urea and creatinine) were specifically determined on day 6 following surgery to assess tolerance to the infused emulsion.
Statistical analysis
Student's t test and Fisher's exact test were performed. Significance was set at a P value < 0·05. SPSS 13.0 was used for the calculations (SPSS, Inc., Cary, NC, USA).
The present study was conducted according to the guidelines stated in the Declaration of Helsinki, and all procedures involving human patients were approved by the ‘Comitè Ètic d'Investigació Clínica de l'Hospital Universitari de Bellvitge’. Written informed consent was obtained from all patients.
Results
Clinical characteristics
Initially, twenty-nine patients were randomised, but two patients were excluded. Among the twenty-seven patients assessed (median age 65 years; range 32–84), 66·6 % (n 18) were men.
Twelve patients had large gastric adenocarcinoma (IIIA or IIIB). All the surgeries were open total gastrectomy with large lymphadenectomy; splenectomy was performed in six cases and pancreatectomy in four cases. In seven cases, a partial colectomy and partial small intestine resection were performed. Blood transfusion was necessary in ten cases. PN was indicated because the option of performing a successful jejunostomy for feeding was not considered an option.
Ten patients had pancreatic ductal adenocarcinoma (IIB or III). They underwent open duodenopancreatectomy, and all received blood transfusion, and in all but one, surgery took 6 h or more. After this kind of intervention, PN is the support diet regimen most frequently used in our hospital.
Three patients had oesophageal adenocarcinoma (IIB or III). They underwent open oesophagectomy (radical resection and reconstruction), and gastrectomy was also performed in two cases. They received PN because their nutritional status before the intervention was not considered adequate.
Two patients underwent colectomy, both with open surgery. One patient underwent a total colectomy with partial resection of small intestine because of a massive polyposis. The other patient underwent a combination of colectomy, hysterectomy, pancreatectomy and partial gastrectomy because of a gynaecological cancer with metastasis. Both patients received blood transfusion and finished with one or more stomata. The length of these interventions was over 6 h. They received PN because of the extensive resections.
Fourteen patients received standard PN (group A), and thirteen patients received PN supplemented with FO (group B). The baseline characteristics of both groups are presented in Table 1. Use of concomitant medication and blood-related products showed no significant differences (data not shown). PN administration was carried out with no side effects in any case, and there were no reported problems in this regard. The nutrients administered are presented in Table 2.
Table 1 Baseline patient characteristics
(Mean values and standard deviations; n and percentages)
OO, olive oil; FO, fish oil.
* Student's t test.
† Fisher's exact test.
Table 2 Parenteral intake, inflammatory response, emulsion safety and outcomes
(Mean values and standard deviations; n and percentages; medians and interquartile ranges (IQR))
OO, olive oil; FO, fish oil; GGT, γ-glutamyltransferase; ALP, alkaline phosphatase; ALT, alanine aminotransferase; PN, parenteral nutrition.
* Student's t test.
† Fisher's exact test.
Outcomes
Mortality, sepsis, infectious complications, hospital stay and PN duration are presented in Table 2. The only statistically significant difference was found in infectious complications: eleven in group A (three respiratory, three abdominal, four urinary and one surgical wound) and three in group B (one abdominal, one surgical wound and one bloodstream infection) (P = 0·007).
Inflammatory response and safety of the infusions
No significant differences were found between the groups (Table 2).
Discussion
A significantly lower incidence of non-septic infection was observed in the FO-supplemented group.
FO acts as an immunomodulator(Reference Waitzberg, Torrinhas and Jacintho8–Reference Mertes, Grimm and Fürst14) with protective properties in the hyperinflammatory state of postoperative patients(Reference Schlotzer and Kanning13). The low content of n-6 and high-α-tocopherol(Reference Antébi, Mansoor and Ferrier15) may contribute to an improvement in the oxidative state by minimising lipid peroxidation(Reference Schlotzer and Kanning13). It must be emphasised that this outcome may be attributed to FO, but the influence of any particular component of this emulsion has not been studied in the present study.
Results of related studies are in agreement with the fact that the infection rate is lower in groups that receive FO, but the differences found have not been shown to be statistically significant(Reference Wanten and Calder11, Reference Senkal, Geiger and Hannemann16). Indeed, the overall incidence of non-septic infection in the present study is high, which could be attributed to the fact that the patients who were selected were seriously ill, and had undergone quite complicated major surgery; nevertheless, no significant difference was observed for sepsis between the groups.
Differences regarding mortality were NS, which was consistent with other studies(Reference Tsekos, Reuter and Stehle2, Reference Heller, Rössler and Lits6, Reference Grecu, Mirea and Grintescu17, Reference Wang, Li and Li18). The high rate of mortality observed in the present study could be attributed to the facts that all the diseases were malignant in a high stage and were treated through open surgery and in long interventions, and that the albumin values before the intervention were low.
Clearly, there are two main limitations to the present study: the small sample size and the lack of more inflammatory and immunological markers. However, it should be noted that the main focus of the study was the patients' clinical outcome.
This is the first study that has compared the addition of FO to an emulsion based on OO that has proven metabolic efficacy and safety(Reference García-de-Lorenzo, Denia and Atlan19) and, in some studies, immunoneutral properties(Reference Grimm, Mertes and Goeters20). It has been hypothesised that FO emulsions may have an associated immune suppression which could reduce the host resistance to infection(Reference Puertollano, Puertollano and Álvarez de Cienfuegos5). The present results provide statistical support to the idea that the protective activity of these lipids and the high amounts of vitamin E predominate over an immunosuppressive effect with possible enhanced susceptibility to infection. The maximum dose of FO is established at 0·2 g/kg per d(Reference Heller, Fischer and Rössel1, Reference Heller, Rösel and Gottschlich7), although the proper balance between n-3 and n-6 remains uncertain. In the present study, the ratio was 1:1·6, with a content of 0·13–0·16 g of FO/kg per d.
In conclusion, this is the first PN study that attempted to define the impact of FO supplementation v. an OO-based emulsion. The strength of the study in a limited number of high-risk surgical patients during 5 d of PN was not sufficient to assess the overall impact of OO v. FO supplementation. Nonetheless, the FO-supplemented regimen demonstrated a clear and statistically significant reduction in non-septic infection. Further studies in larger patient populations with more extensive investigation of specific inflammatory markers are needed to reassess these findings.
Acknowledgements
The authors would like to thank the staff of the Departments of Gastrointestinal Surgery and Pharmacy, and Celine Cavallo and Jonathan Rogerson for the translation. There are no conflicts of interest. The translation was funded by IDIBELL. M. B. B.-T. carried out the studies and data analyses and drafted the manuscript; J. M. L.-T. conceived the study, carried out the statistical analysis and corrected the manuscript; E. L.-B. participated in the design of the study and corrected the manuscript; S. B.-A. and L. F.-T. participated in the design and coordination of the study; J. M. R.-T. and R. J.-M. revised the manuscript. All authors read and approved the final manuscript.
